丙酸倍氯松气雾剂防治支气管哮喘18年总结  

Effect of inhaled Beclomethasone Dipropionate (BDP) on prevention and management of bronchial asthma in Children: Eighteen years' experience

作　　者：戴家熊[1] 韩连书[1] 包军[1] 鲍一笑[1] 苏渊[1] 

机构地区：[1]第二军医大学长征医院儿科,200003

出　　处：《临床儿科杂志》1999年第2期70-72,共3页Journal of Clinical Pediatrics

摘　　要：1977年至1995年我科应用丙酸倍氯松气雾剂(BDP)防治小儿哮喘千余名,平均剂量为300μg·d,疗程2.16±1.52年。对其中399例患儿进行了长期随访,考核临床疗效,并行肺功能、气道高反应性、外周血淋巴细胞CD23表达、肾上腺皮质功能、咽部霉菌和身高体重的测定。结果显示:临床有效率达84.21％,对照组为24.39％(P<0.01),早晚PEF显著增加。气道高反应性下降,外周血淋巴细胞CD23阳性率降低,血浆皮质醇、ACTH含量与身高、体重均在正常值范围内。我们总结了4项措施使其疗效高达98％。本文显示长期吸入BDP可使哮喘得到理想控制,并可降低气道高反应性而无全身副作用。Inhaled Beclomethasone Dipropionate (BDP)were administered in 399 children with asthma during 1977 to 1995 at the average dosage of 300μg/d and the duration of 2. 16 ±1. 52 years. The clinical effect, the pulmonary function, the bronchial hyperresponsiveness, the expression of CD23 in the peripheral lymphocyte, the function of adrenal cortex, the determination of throat fungus, and the measurement of stature and body weight were carried out in these patients, respectively. The results showed that the effective rate was 84. 2% compared to 24. 9% in the patients without inhaled BDP(P<0. 01). There were an significant increase of the pulmonary function in both of morning and evening, and the considerable decreases of both of the bronchial hyperresponsiveness and the positive rate of CD23 in the peripheral lymphocyte. It was also found that the levels of plasma cortisol and ACTH, and stature and body weight were all in the normal limitation. It is concluded that the most asthmatic patients can be controlled effectively with the longer use of inhaled BDP which may be valuable to be economic, easy to use and without side -effects.

关 键 词：丙酸倍氯松 哮喘 药物疗法 气雾剂 

分 类 号：R562.250.5[医药卫生—呼吸系统]